However, this enthusiasm has subsequently decreased, considering that the KRAS G12C mutation is not the most frequent one for mCRC patients and considering that the response to treatment and overall survival data for KRAS G12C inhibitors in latter line turned out to be less exciting in tumors with mCRC than in lung cancer. This evidence concerns the gene KRAS and lung carcinoma.